Clearmind Medicine Inc.
No enriched coverage for $CMND in the last 7 days.
No SEC Form 4 filings for $CMND in the last 30 days.
See all $CMND insider activity →Clearmind Medicine's (CMND) subsidiary, Charging Robotics, launched a wireless EV-charging platform for autonomous fleets, offering up to 10 kW power and 95% efficiency. The system uses AI for energy management and supports unattended charging. CMND closed at $6.58, unchanged in premarket.
Clearmind Medicine (Nasdaq: CMND) announced a patent publication in Japan for a 3-MMC-based treatment for dyskinesia, a neurological movement disorder. The patent also covers combinations with Palmitoylethanolamide (PEA). This development is part of a collaboration with NeuroThera Labs (TSXV: NTLX). The company aims to strengthen its intellectual property portfolio in neurological disorder treatments.
Clearmind Medicine (CMND) submitted recommendations to the FDA for streamlined reviews of non-hallucinogenic neuroplastogen therapies. The company's research at Yale and Johns Hopkins aims to treat conditions like Alcohol Use Disorder with self-administered, at-home treatments. CMND is down 2.40% at $5.70.
Recent CMND coverage spans technology, regulation and mergers & acquisitions.
Wireless, connector-free charging for autonomous fleets is a product milestone that could support commercialization expectations, but it is not yet tied to revenue or contracts in the article.
The new patent strengthens CMND's IP position and may improve future valuation if the therapy advances.
The filing may be viewed as a step toward streamlined approval, potentially lifting the stock modestly.
The filing may boost investor optimism if it leads to favorable regulatory outcomes, but uncertainty remains.
FDA hearing highlights regulatory interest in non‑hallucinogenic psychedelic programs.
AlphAI scores every news story that mentions CMND with an AI model for sentiment and relevance, and aggregates insider trades from Clearmind Medicine Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Clearmind Medicine's (CMND) subsidiary, Charging Robotics, launched a wireless EV-charging platform for autonomous fleets, offering up to 10 kW power and 95% efficiency. The system uses AI for energy management and supports unattended charging. CMND closed at $6.58, unchanged in premarket.
3 min readClearmind Medicine (Nasdaq: CMND) announced a patent publication in Japan for a 3-MMC-based treatment for dyskinesia, a neurological movement disorder. The patent also covers combinations with Palmitoylethanolamide (PEA). This development is part of a collaboration with NeuroThera Labs (TSXV: NTLX). The company aims to strengthen its intellectual property portfolio in neurological disorder treatments.
1 min readClearmind Medicine (CMND) submitted recommendations to the FDA for streamlined reviews of non-hallucinogenic neuroplastogen therapies. The company's research at Yale and Johns Hopkins aims to treat conditions like Alcohol Use Disorder with self-administered, at-home treatments. CMND is down 2.40% at $5.70.
2 min readClearmind Medicine (NASDAQ:CMND) submitted FDA recommendations on psychedelic therapies, focusing on non-hallucinogenic treatments and patient access. The company cited ongoing clinical trials and called for collaborations with U.S. federal agencies. Clearmind develops psychedelic-derived compounds for various disorders and holds 32 granted patents.
2 min readAethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.
3 min readClearmind Medicine (CMND) presented at an FDA hearing on psychedelic drugs, discussing patient access. The company's Chief of Global Impact shared insights from its MEAI clinical trial at Yale and Johns Hopkins, suggesting non-hallucinogenic treatments could expand access. CMND's stock is up 21.72% to $0.97.
2 min readClearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.
2 min readClearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.
2 min readClearmind Medicine (CMND) shares fell 14% after it agreed to buy a 51% stake in Charging Robotics for $2.5M, including a $1.5M loan at 4% interest. CMND stock is trading at $1.45, down from $1.70.
1 min readClearmind Medicine Inc. (Nasdaq: CMND) agreed to acquire a 51% stake in Charging Robotics, a wireless charging solutions provider for automated parking and robotaxis, for $2.5M. The deal includes a $1.5M loan at 4% interest. Closing is expected by September 7, 2026, subject to conditions. Charging Robotics' technology offers up to 10 kW continuous charging with smart vehicle communication.
2 min read